Page 2 - Zydus Lifesciences Ltd News

Zydus Life stock price jumps 6% on USFDA nod for Valsartan tablets

The shares surged after the pharmaceutical major announced that it has secured final nod from United States Food and Drug Administration (USFDA) for Valsartan tablets.

Gland Pharma, Zydus Lifesciences secure USFDA approvals for key medications

Gland Pharma, a Hyderabad-based generic injectable-focused company, received tentative approval for Latanoprostene Bunod Ophthalmic Solution, 0.024 per cent

Zydus Life Vadodara facility gets OAI report from USFDA, stock falls 3%

The fall in the stock came after the company announced that it has secured an Official Action Indicated (OAI) report from the United States Food and Drug Administration (USFDA).

Zydus Lifesciences hits all time high on USFDA nod for multiple drugs

Shares of Zydus Lifesciences zoomed up to 1.93 per cent, hitting its all time high at Rs 1203.20 per share on the BSE in Thursday's intraday trade

Zydus Life gets USFDA approval to market heart failure treatment drug

Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to market its generic Sacubitril and Valsartan tablets combination used to treat chronic heart failure in adults. The approval by the US Food and Drug Administration (USFDA) is to market Sacubitril and Valsartan tablets of strengths 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg, Zydus Lifesciences said in a regulatory filing. Sacubitril and Valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company added.

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.